Since the year 2000, biotech-sector businesses in France have managed to raise an aggregate total of €2.92 billion. In terms of the number of new molecules being developed, France ranks 4 th worldwide. Today, French-based companies are turning their attention to international markets and the opportunities they offer. France has succeeded in developing genuine expertise and internationally recognised know-how in the biotech field, even though this is still a young industry.
When it comes to biotechnologies, French-based companies are cutting edge. According to Leeme , the federation of French medical-sector companies, today, France numbers close to 390 biotech-sector players. Biotech France , another French industry association for biotech companies, indicates that a third of these companies have been in existence for over 10 years.
And yet, the number of businesses created in this field is growing very fast: in 2012 alone, 50 companies were set up. This is clear evidence that there is real entrepreneurial effervescence when it comes to R&D and the biotech industry in France.
French biotech players are mainly recently formed start-ups and SMEs. Only 4% of biotech-sector businesses have over 100 employees; on average, they employ 22 people.
As to the type of activity, most French companies in the sector specialize in human sciences, with therapeutic products that are concentrated on the treatment of cancer.
“The French have developed a fully fledged know-how on cardio-vascular devices, infectious diseases, dermatology, blood diseases, and for surgery,” explains Yves Germani, in charge of the Health Sector at the French Trade Commission UBIFRANCE in North America.
Altogether, the French biotech industry generated €261 million in turnover in 2011, as compared with €186 million in 2010. As for companies listed on the stock market, they generated €369 million in sales.
Concerning the pipeline — i.e. the term used in the industry to indicate the number of molecules being developed — France ranks 4th, behind the UK, Germany, Switzerland and Israel. This is a commendable ranking, even if it can and should be improved.
When their results are examined in detail, it appears that — depending on the stage of development they have reached — French companies create more products at the pre-clinical phase. This is completely logical, since it concerns products that have been developed before the relevant clinical trials with patients have taken place...
Between the start of the development process for a new medicine and the release of a new molecule on the market, it can sometimes take up to 10 years. Unfortunately, a consequence of this is that a number of products fall by the wayside. It should be pointed out, however, that, since 2008, French companies have released and sold more and more new products. To put it another way, as Yves Germani of UBIFRANCE North America points out, “French companies don’t just do research: they discover!”
French-based biotech companies tend to have smaller R&D budgets than their European and international competitors. Clearly, this is not preventing them from innovating and, fortunately, the size of the venture-capital sector is growing fast in relation to the biotech industry in France.
To give an overall picture, the funds raised by French biotech players increased by 63% between 2009 and 2012, reaching €178 million. Since the year 2000, biotech-sector businesses in France have managed to raise an aggregate total of €2.92 billion.
Today and quite naturally, French-based companies are turning their attention to international markets and the opportunities they offer, in order to find new partners and new sources of funding. Evidence of this is that SMEs such as Affilogic, Imabiotech, Interactive Biosoftware, MedinCell or O4CP are all reaching out with confidence to biotech-industry and finance-sector players based in mature markets — from the USA and Canada to Western Europe.
For further information about the French Trade Commission UBIFRANCE in the UK, please go to: http://www.ubifrance.com/uk/
Biotechnology, Pharmaceuticals ( 7
Boiron will showcase Camilia®, a natural remedy for teething and related symptoms in babies and young children, at The Baby Show in Birmingham (UK) from 17 to 19 May 2013. Camilia® was launched on the British market on 1 May 2013 and is now available in a number of pharmacies.
Boiron launched Camilia®, a natural remedy for teething and related symptoms in babies and young children, in the UK on 1 May of this year. The company will showcase this remedy on Stand H10 at The Baby Show, the leading pregnancy and parenting event, to be held in Birmingham (England). The Baby Show is taking place from 17 to 19 May at the National Exhibition Centre (NEC).
Camilia® treats infant teething pains as well as related symptoms, such as crotchety behaviour, swollen gums, sore bottoms and profuse salivation. Thanks to its exclusive formula, which combines three natural substances — Chamomilla vulgaris 9c, Phytolacca decandra 5c and Rheum 5c — and purified water, Camilia® has been the remedy of choice for infants from Canada to Tunisia since it was first developed in the mid-1990s.
A liquid with a neutral taste, Camilia® contains no artificial colouring, no preservatives, no sugars, no lactose and no ethanol. The medication comes in sterile, drinkable single doses, which is ideal from the point of view of hygiene and makes it easy to administer to babies and toddlers.
Packaged in boxes of 10 single doses, Camilia® has a recommended retail price of £6.95 per box in the UK. The remedy can be bought over the counter (i.e. without mandatory medical prescription) from pharmacies and health food stores, as well as through many online-sales sites.
Teething generally occurs in children under the age of 2 ½ years, i.e. between three and 30 months. Teething is frequently accompanied by symptoms that are disagreeable for the infant and his (or her) family and carers, such as hyper-salivation, digestive troubles (linked themselves to a modification of the intestinal acidity, or pH), behavioural problems (including irritability and disturbed sleep), and associated ENT disorders (rhino-pharyngitis, etc.).
For Jérôme Delannoy, Export Director at Boiron, "The aim is that this medication should become a benchmark in Great Britain for all parents who are searching for a solution to treat easily, and without attendant side effects, their infants’ teething pains."
Boiron was set up in 1932, when Jean and Henri Boiron, the company’s founders, who were scientists and entrepreneurs at heart, launched the company.
In 2013, Boiron remains an independent, family-run laboratory — something of an exception in the international pharmaceuticals industry. Christian Boiron, son of Jean Boiron, is the company’s Director-General.
The company’s independence means that Boiron remains the master of its strategic choices. Boiron makes medications that are useful to public health and available to everyone — be they health professionals or the general public.
Today, the group is present in nearly 80 countries and continues the work of its founders, who were pioneers in the development of homeopathic medications worldwide.
In 2012, Boiron had a turnover of £488 million and employed 3,800 staff. The company is headquartered in Lyons (south-eastern France) and has a representative in London (UK).
Boiron will be on Stand H10 at The Baby Show, which is taking place at the NEC, in Birmingham (UK), from 17 to 19 May 2013.
For further information about the trade show, please go to: http://www.thebabyshow.co.uk/
For further information about the company, please go to: http://www.boiron.com/
For further information, please contact :
Quote ref. : FTPB3854
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
View other press releases at :
On 17 April 2013, on the premises of the French Trade Commission UBIFRANCE in central London, three executives from Boiron, in France, gave a press conference concerning Camilia®, the homeopathic medicine for treating teething pains in babies and young children that is being launched in the UK.
You will find, below, the full text of the three speakers’ interventions. Further details are available on request, and interviews can be arranged face to face or over the telephone (depending on the schedule of the three executives concerned).
For the Power Point of the presentation that was given during the press conference, on 17 April, here in London, please click here:
Should you wish to have any further information, please contact Ms Katherine Woods, Press Officer, on 0207-024-3612 or firstname.lastname@example.org .
Profile of Speakers at the Press Conference held on 18 April 2013 in London (UK)
▪ Dr Laurence Terzan is the Medical Director at Boiron. Dr Terzan is an epidemiologist with a Diplôme National de Santé Publique (France’s National Public Health Diploma) as well as qualifications from Centre d’Enseignement et de Développement de l’Homéopathie (the Centre for the Teaching and Development of Homeopathy) that she earned in 1994 and 1998 respectively.
▪ Mr Jérôme Delannoy is Export Manager of Boiron: a trained veterinary surgeon, he has worked in the pharmaceutical industry for 25 years. He began his career in the animal-health sector, which led him to live in Southern Africa and, then, to travel worldwide. Mr Delannoy next worked in various human-health pharmaceutical laboratories. Since 2004, he has been Regional Director for Boiron, managing business operations in the UK, in addition to other countries.
▪ Mr Jean-François Lurol is Director of External Relations at Boiron. He studied at the Ecole Française des Attachés de Presse (France’s School for Press Officers) in Lyons (South-Eastern France), and is now a member of the Club de Presse de Lyon (Lyons’ Press Club) and of the Syndicat National des Attachés de Pre sse (France’s National Press Officers’ Union).
Mr J F Lurol, Director of External Relations at Boiron: An overview of Boiron and Camilia®
“Good morning, Ladies and Gentlemen,
“I am Jean-François Lurol, Director of External Relations at Boiron laboratories.
“I am very happy to be here for this press conference. Thank you for coming and, most importantly, please excuse my terrible French accent!
“In England, scepticism is important regarding homeopathy. You probably know this. We cannot leave things the way they are. Homeopathy is a therapy. It has been part of medicine for 200 years and it is very helpful to patients and health professionals. Our medicines [at Boiron] are efficacious and they are used daily by millions of people. They are safe and present no health risk. Boiron’s responsibility is to make this reality known.
“That is the reason why we have an R&D programme. Our medicines are assets for public health and we want to pass this message on to everyone. So, we are here to talk about the launch of our medication — Camilia®. For us, this is a great novelty. Indeed, Camilia® is the first medication that we distribute in the UK.
“I will not say any more about Camilia®. My colleagues will do a better job of it than I would. Now, I would like to introduce them to you. I will start with Mr Jérôme Delannoy, Export Manager. He will tell you why and how we are launching this medication across the UK.
“I would also like to introduce you to our Medical Director, head of our research department, Dr Laurence Terzan. She will talk about teething pains in infants and the possibilities offered by a homeopathic medicine such as Camilia®.
“Following these presentations, we’ll be pleased to answer your questions. Before handing over to Jérôme Delannoy, I would like to talk shortly about Boiron.
“Our company, Boiron, was created 100 years ago. Jean and Henri Boiron, the company’s founders, were scientists and developers at heart. Nowadays, Boiron remains an independent, family-run laboratory — this is an exception in the international pharmaceutical field. Christian Boiron, the son of Jean Boiron, is the company’s General Manager.
“The company’s independence means that Boiron is driven by (and makes) its own strategic choices. Boiron provides useful and safe medications for health professionals and the general public. It contributes to public health.
“Today, the group is present in nearly 60 countries and continues the work of its founders, who were pioneers in the development of homeopathic medications worldwide.
“In 2012, Boiron had a turnover of £480 million and employed 3,900 staff. The company is headquartered in Lyons (in South-Eastern France) and has a representative in London (UK).
“Thank you for your attention. I will give the floor to Jérôme Delannoy.”
Mr Jérôme Delannoy, Export Manager, about the launch of Camilia® in the UK
“Good morning Ladies and Gentlemen,
“I am delighted to welcome you here today for the launch of our new product, Camilia® Oral Solution.
“This is a very important event for our company, as it is our first OTC product to be marketed in the UK.
“We have several reasons to be satisfied, as I will explain.
“Firstly, in relation to the Marketing Authorisation we have secured: Camilia® is a pharmaceutical product and we have been granted a Marketing Authorisation two years only after submission to the Ministry of Health [in the UK]. This may sound like a long time but, indeed, this is rather short for a pharmaceutical-product assessment.
“If the assessment went so quickly, this is due to the quality of the medical information provided in our technical files submitted to the MHRA, which delivers Marketing Authorisations [in Britain].
“Secondly, we are proud to launch a product which brings a simple, efficacious and healthy solution to teething pains in babies and toddlers. This product will improve the quality of life of these children but, also, of their parents!
“Let me, now, give you a few details about Camilia®.
“First of all, what is Camilia® Oral Solution, and what is it used for?
“Camilia® Oral Solution is a homeopathic medicinal product used within the homeopathic tradition for the relief of teething pain and other minor symptoms associated with teething in babies and toddlers.
“Second, how to administer Camilia® Oral Solution?
“Regarding the dosage, Camilia® Oral Solution is suitable for use by babies aged between one month and two years, and young children aged between two and six years.
“The usual dose is the contents of a single-dose unit, two to three times a day. This solution is for oral use only.
“As for the duration of the treatment, this medicine should not be used for more than three days. If symptoms worsen or persist after three days, a doctor or qualified healthcare practitioner should be consulted.
“In a few moments, Dr Laurence Terzan will give you more medical details about Camilia®. Nevertheless, I would like to insist on a few product characteristics [as follows].
“No1, the efficacy of Camilia® has been reported by many parents.
“No2, Camilia® is safe because it is free of lactose, ethanol, flavourings or preservatives.
“No3, Camilia® is easy to use because it consists of [a dose of] 1ml of liquid to pour into the baby’s mouth, and the product has no taste [which reduces risks of rejection by the baby].
“No4, Camilia® is ready to use: there is no need to dilute a powder.
“No5, Camilia® is a hygienically safe product, because the single-dose containers are sterile and protected by an aluminium foil sachet. Thus, it is also easy to carry along [when parents are on the move with their baby].
“Since we are talking about teething in babies, you know that children love stories. Do you know that Camilia® already has a nice story to tell? Our product is manufactured in France, near Euro Disney [i.e. Disneyland® Paris]…but Camilia® was not born in France. The product was first marketed in Canada, in 1994.
“Since then, Boiron has launched Camilia® in several countries: France, the USA, Canada, Russia, Switzerland, Tunisia, Poland…and, everywhere, Camilia® has achieved huge success amongst members of the public. For example, last year , in France, an average of five boxes of Camilia® were sold per new-born baby.
“More recently, and to satisfy market demand, we have launched larger pack sizes, such as boxes with 20 or 30 single-dose containers. This will, hopefully, also happen later in the UK.
“Camilia® will be available from 1st May 2013 onwards in London, but also in the rest of the UK.
“Our product is stocked and distributed by Alliance Healthcare. Thus, Camilia® could be bought or ordered from any pharmacy, even if we have a closer partnership with the Alphega pharmacies.
“We are also implementing a two-stage communication plan.
“First of all, towards healthcare professionals and, more particularly, pharmacists, midwives, and health visitors: parents will be able to seek advice from these professionals.
“Also, directly to potential users: communication tools will be available at points of sale. Advertisements will be placed in the major parenting magazines.
“A website is also under construction to supply updated information on Camilia®. It will also include a pharmacy locator to find the nearest retail point. The recommended retail price for Camilia®, at launch, is £6.95 per standard-size pack [in the UK].
“We are all very excited about this first launch and we hope that more Boiron products will follow soon. And, now, I will hand over to our medical director, Dr Laurence Terzan.”
Dr Laurence Terzan, Medical Director of Boiron, about Camilia®’s medical properties and proven effectiveness
“It is a pleasure for me to meet you, and share with you some information about Camilia®.
“I am the Medical Director of the Research Division of Laboratoire Boiron, in France.
“Today, I will present to you our medicine, Camilia®, and some results about Camilia® in relation to teething symptoms, through a study we have carried out.
“First of all, Camilia® is a homeopathic medicine that is indicated in the teething of babies. Camilia® has a therapeutic impact on both general and local symptoms. It acts fast to relieve the symptoms [of teething].
“Camilia® is made from natural plants [as follows].
“ Calendula officinalis , also known as the English marigold, possesses antiseptic as well as anti-inflammatory properties. It is used in dermatology and stomatology. Chamomilla Vulgaris, for its part, is indicated for teething. It will relieve gingival and dental pain and alleviate fever. Furthermore, as it has sedative properties, it will lessen the baby’s irritability.
“ Phytolacca decandra , commonly known as Poke Root, is a herb. It is used for the treatment of pharyngitis, gingivitis and sore throat, which can accompany teething.
“ Rheum officinale is a medicine made out of a plant — rhubarb roots. This medicine is indicated for the treatment of abdominal pain, including soft saddles and diarrhoea, as induced by teething.
“One important point to highlight is that Camilia® has no side effects, and this is a key advantage, especially to parents.
“The presentation of Camilia® as a single dose is safe. It can be associated to gels when the symptoms are marked.
“Teething is a natural occurrence in childhood, usually beginning at around four months and continuing until the age of two years.
“However, teething symptoms are not really described in the medical literature as they are not considered to be a medical complaint: there is no existing consensus regarding the symptoms attributable to teeth development and there are no guidelines for their treatment. Teething-symptoms management is a recurrent concern in paediatric practice.
“Let me briefly present to you the study we carried out about Camilia®.
“First of all, the aim of the study: it was to describe teething symptoms and evaluate their management by paediatricians with the help of Camilia® (our homeopathic medicinal product) and Delabarre® as well as Dolodent® (which are gingival gels): all are common treatments indicated, in real-life medical practice [for teething problems in young children].
“Second, the method that we used: this prospective, observational study involved 161 French paediatricians, who agreed to participate and filled out case reports for the first four children aged three to 24 months that they treated for teething.
“Medical and treatment dates were collected at baseline and at seven days, if a follow-up was necessary.
“In parallel, parents were asked to fill out a diary to list symptoms and delivered treatments daily, and to enter details of their level of satisfaction [in view of the treatment and its outcomes] on Day 7.
“And now, the results: the data concerning 597 children at baseline and [contained in] 426 questionnaires was analysed.
“The median age was eight months, 58.50% [of children] were male, and it was the first teething experience for 49.80% of them.
"The mean number of symptoms observed by the paediatricians at the inclusion visit was 4.90. Overall, 96.60 % of children had at least one oral-care/oral-hygiene symptom and 94.30% developed at least one systemic symptom.
“The oral-hygiene symptoms included gum tumefaction, salivation and rashes.
“The systemic symptoms were excitability and irritability; unusual crying; sleep disorders; nappy rashes; soft saddles; diarrhoea; and, finally, bouts of fever.
“A total of 71.20% of the children were prescribed Camilia®: for half of them, it was in association with teething gels.
“Parents were also recommended to administer oral pain relievers and fever reducers, for 68.80% [of them], if necessary: in 94.30% of cases, they opted for Paracetamol.
“The best levels of parental satisfaction regarding the treatment’s effectiveness were reached when Camilia® and teething gels were associated, with an 85.50% satisfaction rate.
“When asked about their intention to use the product prescribed for future teething episodes, the answer was positive for 85.20% [of parents] in the case of Camilia® being used on its own. Positive responses dropped to 75.90% in cases where teething gels alone were used. Finally, positive answers reached a high of 86.90% in cases where Camilia® was administered in association with teething gels.
“The conclusion is clear: the study’s results highlight the fact that paediatricians have integrated homeopathic medicinal product Camilia® into their prescriptions, alone or in association with teething gels. Parents expressed satisfaction with the management provided by their paediatrician [of the infant’s teething problems].
“Homeopathy has been used for over 200 years. In France, homeopathic medicines are distributed and available in all pharmacies — i.e. in about 20,000 of them, all over the country. Patients are used to be prescribed homeopathic medicines. But they can also buy them directly, over the counter [OTC]. The pharmacists give advice about homeopathic medicine. Homeopathy is integrated into the practice of GPs.
“We hope this will also happen in the UK, as it represents a real plus in terms of public health.”
For further information, please contact :
Quote ref. : FTPB3851
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
View other press releases at :
Korilog, an IT specialist that designs solutions facilitating the use of heterogeneous biological information systems, has developed KLAST, a sequence-comparison technology for DNA, RNA and proteins. This technology will underpin new advances in emerging biological fields, be it in relation to the environment, farming, health or biotech.
Korilog, a provider of innovative IT solutions, has launched KLAST, a new high-performance sequence-comparison technology. This technology has stemmed from the company’s collaboration with the GenScale research team at Inria, the government-funded computer-sciences R&D centre based in Rennes, in Britanny (western France). GenScale focuses on the analysis of large-scale genomic data.
KLAST allows specialists to search quickly and accurately for similarities in biological sequences (DNA, RNA and proteins). The technology is specially designed to process the large amounts of data produced by next-generation sequencing.
Patrick Durand, Director at Korilog, explains, “One of the key issues when searching for similarities between sequence databanks is to reduce considerably execution time, while simultaneously maintaining high quality in the resulting data.”
Patrick Durand continues, ”Not only does KLAST meet both of those objectives, but its innovative implementation method takes into account the laboratories’ existing computer infrastructure. Indeed, it reaches accelerations without the need for additional peripherals, as it makes full use of the multicore processors available in standard office computers or in cluster nodes.”
KLASTp performance has achieved acceleration by a factor of 24 as compared to the technology of reference, known as BLASTp. These results were achieved by running both algorithms on the eight cores in an Apple Mac Pro during the comparison of 2,327 proteins from the populus trichocarpa deciduous-tree species.
The experiments were done using the details of 2.9 million proteins held in the database at the National Centre for Biotechnology Information Reference Sequence (NCBI RefSeq). KLAST was proved to be as sensitive and selective as Basic Local Alignment Search Tool (BLAST) and SSEARCH, which is an optimal local-alignment search tool that uses the Smith-Waterman algorithm.
Dominique Lavenier, Genscale Research Team Manager, finds transferring KLAST to a high-tech company such as Korilog is a gratifying and important step for his research team. As Dominique Lavenier explains, “It allows us to contribute directly to new advances in emerging biological fields, ranging from health to farming and the environment. And comments from end-users are highly valuable in maintaining KLAST’s position as a technological leader in intensive sequence comparison.”
In order to supply users with an advanced platform for sequence-similarity research, the KLAST engine is included in Korilog’s ngKLAST graphics software suite and in a plugin for the KNIME data-analysis platform. As a result, users can simultaneously enjoy the KLAST accelerator and the advanced data-analysis functionalities provided by hosting platforms KNIME or ngKLAST.
Through these software solutions, it is therefore possible to operate KLAST either through command lines or through a rich graphic interface, using anything from an individual workstation to a calculation cluster (such as those available at major research facilities).
This new technology can be applied across all aspects of large-scale sequence comparison in a range of sectors, from health, food and bio-defence to the environment and biotechnology.
Korilog is based in north-western France. The company designs innovative IT solutions that closely associate human-computer interfaces, bioinformatics-analysis methods and biological databanks in order to facilitate the use of heterogeneous biological information systems.
For further information about Inria, please go to: http://www.inria.fr/en/centre/rennes
For further information about Korilog, please go to: www.korilog.com
For further information, please contact :
Ms Katherine WOODS - Press Officer
UBIFRANCE Press Office in London
SW1Y 4SP - UK
Tel: +44 (0) 207 024 3640
View other press releases at :
Minasolve, a developer and manufacturer of innovative ingredients for the personal care and pharmaceutical ingredients markets, will exhibit its new ethyl hexyl glycerine — MinaCare Hexcine — at SCS Formulate. SCS Formulate, the trade show for the cosmetic industry, will take place from 13 to 14 November in Coventry (UK). Minasolve is also looking for a distributor in the UK.
Minasolve will launch MinaCare Hexcine (INCI name: ethyl hexyl glycerine) on Stand 519 at the SCS Formulate trade show to be held at the Ricoh Arena in Coventry (UK) from 13 to 14 November 2012.
This product will complete Minasolve’s range of parabens substitutes, allowing the company to offer a wide array of these substitutes that have excellent moistening and cleaning properties. This range already includes 1,2-hexanediol, capryloyl glycine, caprylyl glycol, hexamidine diisethionate and pentylene glycol.
Minasolve provides ingredients to the cosmetic, pharmaceutical and food industries, delivering its products across five continents. The company is experiencing a strong growth in its activity, with a six-fold increase in turnover in three years, and is developing activity in the UK, where it is looking for a distributor.
Having origins in the pharmaceutical sector, Minasolve uses three European factories approved by the US Food and Drug Administration (FDA). Minasolve’s production method is also under quality-assurance supervision, which enables the company to guarantee a sound production-process control, as well as significant traceability.
Minasolve has confirmed its place in the natural-origin ingredients market thanks to its range of bio-ingredients. The latest ingredient of vegetable origin launched by the company is MinaCare EGCG (INCI name: epigallocatechin gallate), which is extracted from green tea and is known for its antioxidant properties that protect skin from photo-aging.
Minasolve’s pentylene glycol, MinaCare Pentiol Green ECOCERT, which is derived from vegetable raw materials, is popular internationally. This ingredient also improves sustainable development, as it is derived from sugar-cane bagasse or corn cobs, which would otherwise be burned.
The company’s MinaCare Elage ECOCERT (INCI name: ellagic acid) is increasingly used as a replacement for kojic acid in lightening creams. Equally, Minasolve’s high-quality Resveratrol (>98%) which is of vegetable origin and is renowned in Japan, is experiencing stronger and stronger demand.
Finally, Minasolve has also developed cGMP Propyl Gallate, a pharmaceutical excipient that is used as an antioxidant and responds to the latest pharmaceutical-regulation requirements.
Founded in 2007, Minasolve belongs to Minafin Group, which has 540 staff. Minasolve develops activity in the bio-ingredient domain, dedicated to the expansion and manufacturing of innovative ingredients using its production factories and pilot plants. The company focuses specifically on the personal care and pharmaceutical ingredients markets.
The majority of Minasolve’s installations are inspected by the US health authority Food and Drug Administration (FDA).
Minasolve will exhibit at SCS Formulate, the trade show for the cosmetics industry, which will take place from 13 to 14 November at the Ricoh Arena in Coventry (UK).
The two other commercial entities of the Minafin Group are Minakem and Pennakem.
For further information about SCS Formulate, please go to: http://scsformulate.co.uk/
For further information about Minasolve, please go to: http://minasolve.com/
The French Trade Commission, UBIFRANCE will host its first French MedTec Supplier Day on Thursday 5 July 2012 on its premises, in Central London. This B2B event brings together a delegation of five French manufacturers of medical equipment for hospitals and care homes looking for distribution partnerships in the United Kingdom.
New to the UK, these companies will be presenting their business and products on the morning of the 5 th , and will be meeting distributors of medical equipment to hospitals and healthcare establishments in the UK. This will be followed by a networking lunch, in the course of which representatives of companies and suppliers will be able relax over a sandwich and a glass of wine or two.
The French companies taking part in the B2B event are as follows.
- MAIA Woundcare, a specialist in innovative, patented dressings for chronic wound treatment;
- Cousin Biotech, which produces innovative, supple implantable materials for surgical use;
- Laboratoires Anios, which specialises in products for hygiene as well as the cleaning and disinfection of hospitals and healthcare establishments;
- Surgiris, a specialist in the design and manufacture of specialist lighting and ceiling pendants for operating rooms;
- HMS-Vilgo, which makes care products for care homes and the domiciliary care market, such as medical beds, hoists, easy chairs and daily mobility aids.
If you are a British distributor looking to source new products, and would like to attend, please contact Katie Docwra, Trade Development Adviser, on 0207 024 3619, or by email : Katie.email@example.com .
In Cell Art, a biotechnology company specialising in nanocarrier technologies for macromolecules (including DNA and RNA) and in the development of innovative vaccines and antibodies, has announced today the launch of a US$33.1 million research-and-development project — the RN Armor Vax Consortium. In Cell Art, together with Sanofi Pasteur (the vaccines division of the Sanofi-aventis Group) and CureVac (a German biopharmaceutical firm specialising in mRNA-based vaccinations), has established the consortium which will evaluate new applications of In Cell Art’s technology in the development of mRNA-based vaccines against infectious diseases.
Chloé Bellocq, CEO of In Cell Art, comments, “In Cell Art, in its internal projects, as through its collaborative work with the major players in the pharmaceutical sector, is very committed to the development of gene-based vaccines. Our recent results, from the work surrounding treatment and prevention of hepatocellular carcinoma by DNA vaccination, demonstrate the potential of gene-based vaccines in both prophylactic and therapeutic applications.”
The RN Armor Vax Consortium collaborative-research project was selected from amongst various proposals submitted following a call for projects entitled Controlling Cellular Machinery, Vaccines. The four-year project has a total budget of US$33.1 million and will be co-funded by the Defense Advanced Research Projects Agency (DARPA, an agency of the United States Department of Defense).
The project’s objective is to validate a new universal-vaccine-technology platform that develops and evaluates mRNA-based vaccines (for both prophylactic and therapeutic vaccines against infectious diseases), and which will be the first of its kind.
The project will authenticate new applications (such as the elaboration and vectorization of mRNA-based vaccines) of In Cell Art’s nanocarrier technology. It will therefore reinforce the company’s leading position in the nano-transport of macromolecules of DNA and RNA.
In parallel with the RN Armor Vax Consortium project, In Cell Art and Sanofi Pasteur signed a non-exclusive option and licence agreement with pre-agreed licence terms. This agreement will enable Sanofi Pasteur to access In Cell Art’s formulation technologies to develop and commercialise mRNA-based vaccines.
Under the terms of this agreement, In Cell Art should receive an initial payment, along with milestone payments at certain clinical stages, and royalty payments on the sales of products. In Cell Art will also receive revenue from sales of the clinical and commercial nanocarrier products that will be contained in the final vaccines.
Bruno Pitard, co-founder of In Cell Art, explains, “This new agreement demonstrates the importance of our nanocarrier technologies not only for gene-based vaccines that use DNA, but also for mRNA-based vaccines. The project will strengthen the position of In Cell Art as a leading company in the sector and the best choice for the use of nanocarrier technologies to deliver macromolecules DNA and RNA.”
CureVac is a global leader in mRNA-based vaccination technologies. It develops mRNA-based vaccines as therapeutic vaccines in oncology and prophylactic vaccines for infectious diseases.
For further information about CureVac, please go to: www.curevac.com
About The Defense Advanced Research Projects Agency (DARPA)
DARPA, established in 1958, seeks to maintain the technological superiority of the US military by funding scientific investigations that span a wide range of activities, from laboratory efforts to the creation of full-scale technology demonstrations in such fields as biology, medicine, computer science, chemistry and physics.
For further information about DARPA, please go to: www.darpa.mil
About Sanofi Pasteur
Sanofi Pasteur, the vaccines division of the Sanofi-aventis Group, offers the broadest range of vaccines, giving protection against 20 infectious diseases. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than €1 million in research and development.
Sanofi Pasteur is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
For further information about Sanofi Pasteur, please go to: www.sanofipasteur.com
About In Cell Art
In Cell Art, which is headquartered in Nantes (in western France), was founded in 2005 and is a member of the Atlanpole Biotherapies cluster of biotechnology excellence, also based in the west of France.
In Cell Art is a privately held biopharmaceutical company specialising in the preclinical and pharmaceutical development of nanocarriers for macromolecular drugs. With a Nobel Laureate amongst its founders and research team, the company has designed new classes of non-toxic vectors that are organised on a nanometric scale, enabling them to cross the cell barrier efficiently and safely. From these vectors, In Cell Art has developed a range of reagents and biotechnology-development services including ICANtibodies® and ICAFectin® transfection reagents, along with a pipeline of nanocarriers for the formulation and delivery of nucleic acid-based drugs.
In the absence of recombinant antigens, ICANtibodies® allows, from an in silico antigenic sequence, the production of the most ambitious functional antibodies against any natively expressed protein (including excreted, nuclear, cytoplasmic or membrane proteins). With ICANtibodies®, In Cell Art has assisted its clients in the production of more than 150 different functional antibodies, in less than two years.
ICAFectin® transfection reagents are innovative synthetic vectors for in vitro nucleic acid delivery. They are becoming the reagents of choice for efficient DNA and siRNA transfections. This is demonstrated by their increasingly common use in studies published in leading journals including the Journal of Biological Chemistry, Nucleic Acids Research, PLoS ONE, PLoS Pathogens, Human Gene Therapy, Journal of Neurochemistry, Experimental Cell Research and Neoplasia.
ICA614 nanocarrier, an innovative DNA synthetic formulation, offers unique, efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile. ICA614 nanocarrier represents a crucial step in DNA-vaccine development, and is currently being tested by major vaccine companies such as Sanofi Pasteur and Merial Ltd.
With R&D programmes in oncology, in infectious diseases, and in cardiovascular diseases, In Cell Art has developed specific nanocarriers that allow efficient delivery of siRNA for the interference with the expression of targeted disease-associated genes.
IN CELL ART works in partnership with, and grants research licences to, companies active in the development of RNAi therapeutic products.
For further information about In Cell Art, please go to: www.incellart.com
Distribution Statement ‘A’ (Approved for Public Release, Distribution Unlimited).
avril 25, 2012
UBIFRANCE, the French agency for international business developement, comes under the aegis of France's Ministry for the Economy, Industry & Employment. UBIFRANCE lies at the heart of France's public-sector export support framework.